How well are we translating biofilm research from bench-side to bedside?

Rumbaugh, Kendra P.

doi:10.1016/j.bioflm.2020.100028

Cited by 20 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding why biofilms are so refractory to treatment and finding new anti-biofilm therapies are priorities in bacteriological research and in industrial R and D [ 45 ]. Our results underline the extent and diversity of biofilm matrix resistance to antibiotic entry in CF-like biofilm; they also provide a platform for more mechanistic exploration of the properties of the in vivo biofilm matrix.…”

Section: Discussionmentioning

confidence: 99%

Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa

et al. 2020

View full text Add to dashboard Cite

In vivo biofilms cause recalcitrant infections with extensive and unpredictable antibiotic tolerance. Here, we demonstrate increased tolerance of colistin by Pseudomonas aeruginosa when grown in medium that mimics cystic fibrosis (CF) sputum versus standard medium in in vitro biofilm assays, and drastically increased tolerance when grown in an ex vivo CF model versus the in vitro assay. We used colistin conjugated to the fluorescent dye BODIPY to assess the penetration of the antibiotic into ex vivo biofilms and showed that poor penetration partly explains the high doses of drug necessary to kill bacteria in these biofilms. The ability of antibiotics to penetrate the biofilm matrix is key to their clinical success, but hard to measure. Our results demonstrate both the importance of reduced entry into the matrix in in vivo-like biofilm, and the tractability of using a fluorescent tag and benchtop fluorimeter to assess antibiotic entry into biofilms. This method could be a relatively quick, cheap and useful addition to diagnostic and drug development pipelines, allowing the assessment of drug entry into biofilms, in in vivo-like conditions, prior to more detailed tests of biofilm killing.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Understanding why biofilms are so refractory to treatment and finding new anti-biofilm therapies are priorities in bacteriological research and in industrial R&D (38). Our results underline the extent and diversity of biofilm matrix resistance to antibiotic entry in CF-like biofilm, and provide a platform for more mechanistic exploration of the properties of the in vivo biofilm matrix.…”

Section: Pa14 Sed6 Sed8mentioning

confidence: 63%

Effect of host-mimicking medium and biofilm growth on the ability of colistin to killPseudomonas aeruginosa

Sweeney

Sabnis

Edwards

et al. 2020

Preprint

View full text Add to dashboard Cite

In vivo biofilms cause recalcitrant infections with extensive and unpredictable antibiotic tolerance. Here, we demonstrate increased tolerance of colistin by Pseudomonas aeruginosa when grown in cystic fibrosis-mimicking medium versus standard medium in in vitro biofilm assays, and drastically increased tolerance when grown in an ex vivo CF model versus the in vitro assay. We used colistin conjugated to the fluorescent dye BODIPY to assess the penetration of the antibiotic into ex vivo biofilms and showed that poor penetration partly explains the high doses of drug necessary to kill bacteria in these biofilms. The ability of antibiotics to penetrate the biofilm matrix is key to their clinical success, but hard to measure. Our results demonstrate both the importance of reduced entry into the matrix in in vivo-like biofilm, and the tractability of using a fluorescent tag and benchtop fluorimeter to assess antibiotic entry into biofilms. This method could be a relatively quick, cheap and useful addition to diagnostic and R&D pipelines, allowing the assessment of drug entry into biofilms, in in vivo-like conditions, prior to more detailed tests of biofilm killing.

show abstract

“…When it comes to biofilm infections, it is often difficult to demonstrate biofilm formation and maintenance accurately and convincingly. However, as biofilms are notoriously present in chronic infections, different animal models have been used to evaluate antibiofilm compounds in preclinical trials, as described above …”

Section: Challenges In Translating Abps To the Clinicmentioning

confidence: 99%

“…However, none of these ABPs have yet reached advanced clinical trials. The delay in translating antibiofilm drug candidates into the clinic was recently reviewed by Rumbaugh et al (2020), revealing that most clinical studies for treating biofilms involve the repurposing of drugs or combination of FDA-approved drugs.…”

Section: Challenges In Translating Abps To the Clinicmentioning

confidence: 99%

Antibiofilm Peptides: Relevant Preclinical Animal Infection Models and Translational Potential

Silveira

Torres

Ribeiro

et al. 2021

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Biofilm-forming bacteria may be 10−1000 times more resistant to antibiotics than planktonic bacteria and represent about 75% of bacterial infections in humans. Antibiofilm treatments are scarce, and no effective therapies have been reported so far. In this context, antibiofilm peptides (ABPs) represent an exciting class of agents with potent activity against biofilms both in vitro and in vivo. Moreover, murine models of bacterial biofilm infections have been used to evaluate the in vivo effectiveness of ABPs. Therefore, here we highlight the translational potential of ABPs and provide an overview of the different clinically relevant murine models to assess ABP efficacy, including wound, foreign body, chronic lung, and oral models of infection. We discuss key challenges to translate ABPs to the clinic and the pros and cons of the existing murine biofilm models for reliable assessment of the efficacy of ABPs.

show abstract

How well are we translating biofilm research from bench-side to bedside?

Cited by 20 publications

References 7 publications

Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa

Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa

Effect of host-mimicking medium and biofilm growth on the ability of colistin to killPseudomonas aeruginosa

Antibiofilm Peptides: Relevant Preclinical Animal Infection Models and Translational Potential

Contact Info

Product

Resources

About